SCHEDULE 13D/A: ATAI Life Sciences Updates Stake in COMPASS Pathways to 7.5%
Beneficial Ownership Update
ATAI Life Sciences N.V. and its subsidiary ATAI Life Sciences AG have filed an Amendment No. 4 to Schedule 13D, disclosing a beneficial ownership of 7.5% in COMPASS Pathways plc as of March 5, 2025.
Summary
- ATAI Life Sciences N.V. and ATAI Life Sciences AG (collectively, "ATAI") filed an Amendment No. 4 to their Schedule 13D regarding their beneficial ownership in COMPASS Pathways plc.
- As of March 5, 2025, ATAI AG beneficially owns 6,905,774 Ordinary Shares of COMPASS Pathways plc.
- This represents approximately 7.5% of the 92,673,132 Ordinary Shares outstanding as of February 24, 2025, as reported in COMPASS Pathways' Annual Report on Form 10-K filed on February 27, 2025.
- ATAI Life Sciences N.V. is deemed to share beneficial ownership as the parent company of ATAI AG.
- Neither ATAI nor any related person has conducted any transactions in COMPASS Pathways' Ordinary Shares within the past 60 days.
Sentiment
Score: 5
Explanation: Neutral. This is a factual regulatory filing updating beneficial ownership, with no explicit positive or negative operational or financial news.
Future Outlook
NA
Industry Context
This filing indicates a significant, continued stake by ATAI Life Sciences, a company also focused on mental health and psychedelic-based therapies, in COMPASS Pathways, a leader in psilocybin therapy development. This suggests a strategic alignment or investment interest within the burgeoning psychedelic medicine sector.
Stakeholder Impact
- Shareholders of COMPASS Pathways plc will note the continued significant stake held by ATAI Life Sciences, a key player in the psychedelic medicine space, which may be viewed as a sign of continued strategic interest or confidence.
- Investors will have updated information on the ownership structure of COMPASS Pathways plc.
Key Dates
| Date | Description |
|---|---|
| 2021-05-24 | Original Schedule 13D filed with the SEC. |
| 2025-02-24 | Date as of which 92,673,132 Ordinary Shares of COMPASS Pathways plc were outstanding, as disclosed in their Form 10-K. |
| 2025-02-27 | Date COMPASS Pathways plc filed its Annual Report on Form 10-K, disclosing outstanding shares. |
| 2025-03-05 | Date of event requiring the filing of this Amendment No. 4 to Schedule 13D. |
Keywords
COMPASS Pathways plc, ATAI Life Sciences, Schedule 13D, Beneficial Ownership, Ordinary Shares, CMPS, Biotechnology, Pharmaceuticals, Mental Health, Psychedelics
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.